Quantum BioPharma Ltd C.QNTM

Alternate Symbol(s): QNTM

Healthcare

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Its unbuzzd beverage is a proprietary formulation of vitamins and minerals to help with liver and brain function for the purposes of relieving the effects of alcohol consumption and restoring a normal lifestyle. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

CSE:QNTM - Post by User

Quantum BioPharma Ltd > The Concerned Shareholders Call a Special Meeting

<< Previous

Bullboard Posts

Next >>

Comment by wendhie05on Apr 09, 2021 3:40am

28 Views

Post# 32964978

RE:RE:The Concerned Shareholders Call a Special Meeting

The Company had not held an annual meeting of Shareholders since December 2019, prior to the change in business strategy, and it was time for the Shareholders to have a chance to vote on FSD’s future. The Board (other than Messrs. Durkacz and Saeed) delayed considering the Requisition for several weeks before responding by scheduling a meeting to be held on June 29, 2021, nearly six months after the date of the Requisition.

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale